CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Published on November 13, 2017
![[htbx_corresp002.gif]](htbx_corresp002.gif)
Heat Biologics, Inc.
801 Capitola Drive, Suite 12
Durham, North Carolina 27713
November 13, 2017
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jeffrey Gabor
|
Re: |
Heat Biologics, Inc. |
|
|
Registration Statement on Form S-3 |
|
|
File No. 333-221201 |
Dear Mr. Gabor:
Heat Biologics, Inc. (the Company) hereby requests that the effective date of the Companys Registration Statement on Form S-3 (File No. 333-221201) be accelerated by the U.S. Securities and Exchange Commission to today (November 13, 2017) at 2:00 pm, New York City Time, or as soon as reasonably practicable thereafter.
The Company hereby authorizes Leslie Marlow and Patrick Egan of Gracin & Marlow, LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457, or Mr. Egan at (914) 557-5574 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
|
Very truly yours, | ||
|
|
|
|
Heat Biologics, Inc. | ||
|
|
|
|
By: |
|
/s/ Jeffrey Wolf |
|
|
Name: Jeffrey Wolf |
|
|
Title: Chief Executive Officer |